Skip to main content
logo
Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.0799
-0.0004 (-0.50%)
At close: Aug 1, 2025, 4:00 PM
0.0790
-0.0009 (-1.13%)
After-hours: Aug 1, 2025, 7:59 PM EDT

Despegar.com Revenue

Adaptimmune Therapeutics had revenue of $7.29M in the quarter ending March 31, 2025, with 28.30% growth. This brings the company's revenue in the last twelve months to $179.64M, up 878.53% year-over-year. In the year 2024, Adaptimmune Therapeutics had annual revenue of $178.03M with 195.34% growth.

Revenue (ttm)
$179.64M
Revenue Growth
+878.53%
P/S Ratio
0.11
Revenue / Employee
$355,018
Employees
506
Market Cap
21.18M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2024178.03M117.75M195.34%
Dec 31, 202360.28M33.13M122.05%
Dec 31, 202227.15M21.00M341.50%
Dec 31, 20216.15M2.19M55.36%
Dec 31, 20203.96M2.84M252.76%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
UnitedHealth Group422.82B
Johnson & Johnson90.63B
Merck & Co.63.62B
AbbVie58.33B
AstraZeneca56.50B
Novartis AG55.19B
Eli Lilly and Company49.00B
Novo Nordisk43.92B
Revenue Rankings

ADAP News

More News